Stock Market Live May 4, 2026: S&P 500 (SPY) Sinks on Iran Uncertainty Again

Health and Healthcare

Health and Healthcare Articles

All Health and Healthcare Articles

5864 Articles

Chris Lange | Sep 26, 2014 at 3:41 PM EDT

Coherus Files for IPO: Biotech to Biosimilars

Coherus Biosciences Inc. filed an S-1 with the Securities and Exchange Commission for an initial public offering.

Jon C. Ogg | Sep 25, 2014 at 10:50 AM EDT

Short Sellers Make Moves in Key Biotech Stocks

Short sellers are often active in biotech stocks, and we have seen some excessive short interest activity in the most…

Lee Jackson | Sep 25, 2014 at 8:35 AM EDT

5 Orphan Drug Biotech Stocks to Buy With Big Upside Potential

For many of the top biotech companies, orphan drugs have morphed into huge winners and have even generated other streams…

Jon C. Ogg | Sep 24, 2014 at 11:20 AM EDT

Analyst Now Sees 75% Upside in Sarepta

Credit Suisse's $36 price target on Sarepta Therapeutics effectively calls for close to 75% upside.

Chris Lange | Sep 23, 2014 at 9:15 AM EDT

DBV Technologies Files for IPO, Sort Of

DBV Technologies has filed an F-1 form with the U.S. Securities and Exchange Commission (SEC) for an initial public offering

Chris Lange | Sep 22, 2014 at 2:10 PM EDT

Exagen Diagnostics Files for IPO

Exagen Diagnostics Inc. has filed its S-1 form with the U.S. Securities and Exchange Commission (SEC) for an initial public…

Chris Lange | Sep 22, 2014 at 1:40 PM EDT

A First, Chiropractic IPO Filing: The Joint

The Joint Corporation has filed an S-1 form with the U.S. Securities and Exchange Commission (SEC) for an initial public…

Chris Lange | Sep 18, 2014 at 1:55 PM EDT

Canaccord Genuity Doubles Price Target for Medivation

Medivation received an upgrade from Canaccord Genuity, citing the company’s potential drug sales of Xtandi as undervalued.

Chris Lange | Sep 18, 2014 at 11:40 AM EDT

Flexion Therapeutics Stumbles on Clinical Hold

In the after-hours on Wednesday, Flexion Therapeutics made a hard fall on the news of a clinical hold.

Chris Lange | Sep 18, 2014 at 10:15 AM EDT

Analyst Sees Incyte Worth 70% More

Incyte has serious upside potential, but the inherent risk within it may be too much for some investors to bear.

Chris Lange | Sep 17, 2014 at 10:05 AM EDT

Why Endo Wants to Acquire Auxilium So Much

Endo International made an unsolicited buyout offer to Auxilium Pharmaceuticals, right after the latter announced that it had entered into…

Chris Lange | Sep 16, 2014 at 10:00 AM EDT

Is Avanir Pharma Fully Valued After Monday’s Rally?

Avanir Pharmaceuticals posted amazing gains on Monday following the announcement of a successful Phase 1 trial, but is it now…

Chris Lange | Sep 15, 2014 at 11:35 AM EDT

ReWalk Goes From Marching to Sprinting

Shares of Rewalk Robotics surged again on Monday, following its initial public offering on Friday.

Lee Jackson | Sep 15, 2014 at 10:55 AM EDT

U.S. Hepatitis Problem to Continue Driving These 4 Top Stocks

A new research report from UBS focuses on four top companies that are making great strides in treatments for patients…

Chris Lange | Sep 15, 2014 at 10:35 AM EDT

Alzheimer’s Study Results Take Avanir Back Up to Multiyear Highs

Avanir Pharmaceuticals announced positive Phase 2 results for its drug candidate AVP-923, a potential new therapy for patients with Alzheimer’s…

1 … 280 281 282 283 284 … 392

Health and Healthcare Articles

All Health and Healthcare Articles

Coherus Files for IPO: Biotech to Biosimilars

Short Sellers Make Moves in Key Biotech Stocks

5 Orphan Drug Biotech Stocks to Buy With Big Upside Potential

Analyst Now Sees 75% Upside in Sarepta

DBV Technologies Files for IPO, Sort Of

Exagen Diagnostics Files for IPO

A First, Chiropractic IPO Filing: The Joint

Canaccord Genuity Doubles Price Target for Medivation

Flexion Therapeutics Stumbles on Clinical Hold

Analyst Sees Incyte Worth 70% More

Why Endo Wants to Acquire Auxilium So Much

Is Avanir Pharma Fully Valued After Monday’s Rally?

ReWalk Goes From Marching to Sprinting

U.S. Hepatitis Problem to Continue Driving These 4 Top Stocks

Alzheimer’s Study Results Take Avanir Back Up to Multiyear Highs

Stock Market Live May 4, 2026: S&P 500 (SPY) Sinks on Iran Uncertainty Again

Live Nasdaq Composite: Tech Holds Its Ground as M&A and AI Boom Drown Out Oil Noise

CoreWeave’s Anthropic Deal is Game Changing — The AI‑Infra Trade is Heating Up

After Pentagon Inks Deal With AI Firms, Buy These Under $20 Stocks

Pfizer vs Moderna: Only One Pharma Giant Is a Winner In The Post-Covid Era

American Families' Net Worth Jumped 37% Since 2019, But Their Paychecks Barely Moved

"Sitting on a Tax Time Bomb": Jim Saulnier's Warning to Retiree With $2 Million

Skip the SoundHound Hype — These Three Titans Own the AI Infrastructure Layer That Actually Matters

Joe Rogan’s Audience Is 10 Times More Than Anderson Cooper’s

Health and Healthcare Articles

All Health and Healthcare Articles

Coherus Files for IPO: Biotech to Biosimilars

Short Sellers Make Moves in Key Biotech Stocks

5 Orphan Drug Biotech Stocks to Buy With Big Upside Potential

Analyst Now Sees 75% Upside in Sarepta

DBV Technologies Files for IPO, Sort Of

Exagen Diagnostics Files for IPO

A First, Chiropractic IPO Filing: The Joint

Canaccord Genuity Doubles Price Target for Medivation

Flexion Therapeutics Stumbles on Clinical Hold

Analyst Sees Incyte Worth 70% More

Why Endo Wants to Acquire Auxilium So Much

Is Avanir Pharma Fully Valued After Monday’s Rally?

ReWalk Goes From Marching to Sprinting

U.S. Hepatitis Problem to Continue Driving These 4 Top Stocks

Alzheimer’s Study Results Take Avanir Back Up to Multiyear Highs

Stock Market Live May 4, 2026: S&P 500 (SPY) Sinks on Iran Uncertainty Again

Live Nasdaq Composite: Tech Holds Its Ground as M&A and AI Boom Drown Out Oil Noise

CoreWeave’s Anthropic Deal is Game Changing — The AI‑Infra Trade is Heating Up

After Pentagon Inks Deal With AI Firms, Buy These Under $20 Stocks

Pfizer vs Moderna: Only One Pharma Giant Is a Winner In The Post-Covid Era

Featured Reads

American Families' Net Worth Jumped 37% Since 2019, But Their Paychecks Barely Moved

"Sitting on a Tax Time Bomb": Jim Saulnier's Warning to Retiree With $2 Million